Taro Company Profile

What is the competitive landscape for TARO

TARO has two hundred and sixty approved drugs.

There are five US patents protecting TARO drugs. There are five tentative approvals on TARO drugs.

There are twenty-four patent family members on TARO drugs in eleven countries and two hundred supplementary protection certificates in fifteen countries.

Summary for Taro

International Patents:	24
US Patents:	5
Tradenames:	137
Ingredients:	120
NDAs:	260
Patent Litigation for Taro:	See patent lawsuits for Taro
PTAB Cases with Taro as petitioner:	See PTAB cases with Taro as petitioner

Drugs and US Patents for Taro

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Taro	BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE	brompheniramine maleate; dextromethorphan hydrobromide; pseudoephedrine hydrochloride	SYRUP;ORAL	205112-001	Feb 27, 2017	AA	RX	No	No
Taro	BUMETANIDE	bumetanide	TABLET;ORAL	213458-003	Jul 24, 2023	AB	RX	No	No
Taro	FLUOCINOLONE ACETONIDE	fluocinolone acetonide	OINTMENT;TOPICAL	040041-001	Sep 15, 1994	AT	RX	No	No
Taro	OXICONAZOLE NITRATE	oxiconazole nitrate	CREAM;TOPICAL	205076-001	Mar 7, 2016	AB	RX	No	No
Taro	TOPICORT	desoximetasone	GEL;TOPICAL	018586-001	Mar 29, 1982		DISCN	Yes	No

Expired US Patents for Taro

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Taro	FLO-PRED	prednisolone acetate	SUSPENSION;ORAL	022067-001	Jan 17, 2008	5,881,926
Taro	FLO-PRED	prednisolone acetate	SUSPENSION;ORAL	022067-001	Jan 17, 2008	6,071,523
Taro	FLO-PRED	prednisolone acetate	SUSPENSION;ORAL	022067-001	Jan 17, 2008	6,102,254
Taro	FLO-PRED	prednisolone acetate	SUSPENSION;ORAL	022067-001	Jan 17, 2008	6,399,079
Taro	TOPICORT	desoximetasone	SPRAY;TOPICAL	204141-001	Apr 11, 2013	5,990,100

Paragraph IV (Patent) Challenges for TARO drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Topical Spray	0.25%		2013-12-18
	Topical Lotion	0.5%		2011-03-16

International Patents for Taro Drugs

Country	Patent Number	Estimated Expiration
Canada	2616112
China	101247786
European Patent Office	1898707
European Patent Office	2630951
South Korea	20080044245

Supplementary Protection Certificates for Taro Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1411900	2011C/016	Belgium		PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214
1667986	92172	Luxembourg		PRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL)
2673237	LUC00111	Luxembourg		PRODUCT NAME: SODIUM ZIRCONIUM CYCLOSILICATE; AUTHORISATION NUMBER AND DATE: EU/1/17/1173 20180326
0347066	SPC/GB02/049	United Kingdom		PRODUCT NAME: ESCITALOPRAM OXALATE; REGISTERED: SE 17084/85/86/87 20011207; UK PL 13761/0008 20020610; UK PC 13761/0009 20020610; UK PL 13761/0010 20020610; UK PL 13761/0011 20020610; UK PL 13761/0012 20020610; UK PL 13761/0013 20020610; UK PL 13761/00014 20020610; UK PL 13761/0015 20020610
0591275	SPC/GB05/030	United Kingdom		PRODUCT NAME: NITISINONE (2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/303/001 20050221; UK EU/1/04/303/002 20050221; UK EU/1/04/303/003 20050221

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Taro
• Taro Pharm Inds
• Taro Pharms Ireland
• Taro Pharms North

Pharmaceutical Competitive Landscape Analysis: Taro – Market Position, Strengths & Strategic Insights

In the dynamic world of pharmaceuticals, understanding the competitive landscape is crucial for success. Taro Pharmaceutical Industries Ltd., a global player in the industry, has carved out a significant niche for itself. Let's dive into an in-depth analysis of Taro's market position, strengths, and strategic insights that shape its competitive edge.

Taro Pharmaceutical Industries: An Overview

Taro Pharmaceutical Industries Ltd. is a research-based pharmaceutical manufacturer that has been steadily growing since 2008[1]. Founded in 1950 and headquartered in Haifa, Israel, Taro has established itself as a key player in the development, manufacture, and marketing of prescription and over-the-counter pharmaceutical products[3].

Core Business Model

Taro's business model is multifaceted, focusing on producing high-quality medications across various therapeutic categories[3]. The company's approach includes:

1. Significant investment in Research and Development (R&D)
2. Focus on generic pharmaceuticals
3. State-of-the-art manufacturing facilities
4. Global operations with a strong presence in North America, Europe, and Asia
5. Diverse product portfolio spanning multiple therapeutic areas

Financial Performance

Taro's financial trajectory has been impressive. Its revenues increased from $327 million in 2008 to over $850 million in 2014[1]. This growth trend has been accompanied by a substantial increase in earnings per share, rising from $0.76 to an estimated $13.00 during the same period[1].

Market Position and Competitive Landscape

Taro operates in a highly competitive pharmaceutical market, facing competition from both generic and branded pharmaceutical companies[3].

Market Share

As of Q1 2023, Taro held a market share of 0.26% within the Major Pharmaceutical Preparations Industry[9]. While this might seem small, it's important to note that the pharmaceutical industry is highly fragmented, with even major players like Johnson & Johnson holding around 39.42% market share[9].

Key Competitors

Some of Taro's main competitors include:

1. Teva Pharmaceutical Industries Limited (6.81% market share)
2. Viatris Inc (7.52% market share)
3. Perrigo Company Plc (1.98% market share)
4. Amneal Pharmaceuticals Inc (0.94% market share)[9]

Taro's Strengths in the Competitive Landscape

1. Robust R&D Capabilities

Taro's commitment to research and development is a cornerstone of its growth strategy[7]. The company develops high-quality, proprietary, and off-patent pharmaceuticals for markets worldwide[7]. This focus on innovation allows Taro to continuously expand its product portfolio and stay competitive in the rapidly evolving pharmaceutical industry.

2. Vertical Integration

One of Taro's significant strengths is its vertical integration. The company not only produces finished dosage forms but also synthesizes many of the active ingredients used in its key products[7]. This integration provides Taro with several competitive advantages:

• Quality control over the entire manufacturing process
• Reliability of supply
• Cost advantages in active pharmaceutical ingredients

3. Diverse Product Portfolio

Taro offers a wide range of products across various therapeutic categories, including:

• Dermatology
• Cardiology
• Neurology
• Analgesics
• Gastroenterology[3]

This diversity helps Taro mitigate risks associated with market fluctuations in specific therapeutic areas.

4. Global Presence

Taro has a strong global presence, with operations in over 20 countries[1]. Its key markets include:

• United States
• Canada
• Israel

This global footprint allows Taro to tap into various markets and diversify its revenue streams.

"Taro Pharmaceutical Industries is reported to be on steady growth since 2008. Its revenues have increased from $327 million to over $850 on 2014, and at the same time, its earnings per share have been increasing from $0.76 to an estimated $13.00 during this period."[1]

Strategic Insights: Taro's Approach to Market Dominance

1. Focus on Generic Pharmaceuticals

Taro's strategic focus on generic pharmaceuticals allows it to provide affordable alternatives to brand-name drugs[3]. This approach positions Taro well in a market increasingly focused on cost-effective healthcare solutions.

2. Investment in Manufacturing Excellence

Taro maintains state-of-the-art manufacturing facilities, primarily located in Israel and the United States[3]. These facilities adhere to stringent quality standards, ensuring compliance with regulatory requirements from agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)[3].

3. Multi-Channel Distribution Strategy

Taro utilizes a multi-channel distribution strategy that includes:

• Wholesalers
• Retail drug chains
• Healthcare institutions
• Direct-to-consumer channels[3]

This diverse distribution approach helps Taro reach a wide range of customers and maintain a strong market presence.

4. Customer Engagement Initiatives

Taro emphasizes customer engagement by providing comprehensive support to healthcare providers and patients[3]. These initiatives include:

• Educational resources
• Patient assistance programs
• Direct communication channels

SWOT Analysis: Understanding Taro's Position

Strengths

• Strong market presence
• Extensive distribution networks
• Diverse product portfolio
• Vertical integration
• Robust R&D capabilities

Weaknesses

• Relatively small market share compared to industry giants
• Dependence on generic drug market
• Potential vulnerability to regulatory changes

Opportunities

• Expansion into emerging markets
• Development of new drug formulations
• Potential for strategic partnerships or acquisitions

Threats

• Intense competition in the generic drug market
• Regulatory hurdles
• Potential for supply chain disruptions
• Patent expirations of branded drugs

Future Outlook: Taro's Path Forward

As Taro navigates the future, several factors will likely shape its competitive position:

1. Continued Innovation

   Taro's ongoing investment in R&D will be crucial for developing new products and maintaining its competitive edge.

2. Market Expansion

   Exploring opportunities in emerging markets could provide new avenues for growth.

3. Digital Transformation

   Embracing digital technologies in manufacturing, distribution, and customer engagement could enhance Taro's operational efficiency and market reach.

4. Sustainability Initiatives

   As sustainability becomes increasingly important in the pharmaceutical industry, Taro's approach to environmental and social responsibility could impact its market position.

5. Regulatory Navigation

   Taro's ability to navigate complex and evolving regulatory landscapes will be crucial for its continued success.

Key Takeaways

• Taro Pharmaceutical Industries has shown steady growth since 2008, with significant increases in revenue and earnings per share.
• The company's strengths lie in its robust R&D capabilities, vertical integration, diverse product portfolio, and global presence.
• Taro's focus on generic pharmaceuticals and investment in manufacturing excellence are key strategic approaches.
• While Taro faces intense competition and regulatory challenges, opportunities for growth exist in emerging markets and new drug formulations.
• The company's future success will likely depend on continued innovation, market expansion, digital transformation, and effective regulatory navigation.

FAQs

1. What are Taro Pharmaceutical Industries' main product categories?

   Taro's main product categories include dermatology, cardiology, neurology, analgesics, and gastroenterology.

2. How does Taro's vertical integration provide a competitive advantage?

   Taro's vertical integration allows for quality control over the entire manufacturing process, reliability of supply, and cost advantages in active pharmaceutical ingredients.

3. What is Taro's market share in the Major Pharmaceutical Preparations Industry?

   As of Q1 2023, Taro held a market share of 0.26% within the Major Pharmaceutical Preparations Industry.

4. How does Taro's R&D strategy contribute to its competitive position?

   Taro's significant investment in R&D allows it to continuously develop new and innovative pharmaceutical products, helping it stay competitive in the rapidly evolving industry.

5. What are some of the key challenges Taro faces in the pharmaceutical market?

   Key challenges include intense competition in the generic drug market, regulatory hurdles, potential supply chain disruptions, and patent expirations of branded drugs.

Sources cited: [1] https://www.tarointl.com [3] https://pitchgrade.com/companies/taro-pharmaceutical-industries [7] https://www.taro.com/research [9] https://csimarket.com/stocks/competitionSEG2.php?code=TARO